Increased oxidative stress is related to disease severity in the ALS motor cortex

Neurology

Volumn 84, Issue 20, 2015, Pages 2033-2039

  Ikawa, Masamichi ^a   Okazawa, Hidehiko ^b   Tsujikawa, Tetsuya ^b   Matsunaga, Akiko ^a   Yamamura, Osamu ^a   Mori, Tetsuya ^b   Hamano, Tadanori ^a   Kiyono, Yasushi ^b   Nakamoto, Yasunari ^a   Yoneda, Makoto ^b,c  

^a Faculty of Medical Sciences   (Japan)

^b Biomedical Imaging Research Center   (Japan)

^c UNIVERSITY OF FUKUI   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DIACETYL BIS N4 METHYLTHIOSEMICARBAZONE CU 62; RADIOISOTOPE; UNCLASSIFIED DRUG; COPPER; COPPER (II) DIACETYL-DI(N(4)-METHYLTHIOSEMICARBAZONE); ORGANOMETALLIC COMPOUND; THIOSEMICARBAZONE DERIVATIVE;

ADULT; AGED; ALS FUNCTIONAL RATING SCALE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BRAIN CORTEX; BRAIN MAPPING; CENTRAL SULCUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; FEMALE; HUMAN; MALE; MOTOR CORTEX; OXIDATIVE STRESS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RATING SCALE; SUPERIOR PARIETAL LOBULE; BRAIN; DIAGNOSTIC USE; METABOLISM; MIDDLE AGED; SCINTISCANNING; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; BRAIN; COPPER RADIOISOTOPES; FEMALE; HUMANS; MALE; MIDDLE AGED; MOTOR CORTEX; ORGANOMETALLIC COMPOUNDS; OXIDATIVE STRESS; POSITRON-EMISSION TOMOGRAPHY; SEVERITY OF ILLNESS INDEX; THIOSEMICARBAZONES;

EID: 84929649906     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001588     Document Type: Article

References (37)

1. Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med 2001;344:1688-1700.
2. D'Amico E, Factor-Litvak P, Santella RM, Mitsumoto H. Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis. Free Radic Biol Med 2013;65: 509-527.
3. Manfredi G, Xu Z. Mitochondrial dysfunction and its role in motor neuron degeneration in ALS. Mitochondrion 2005;5:77-87.
4. Lenaz G, Bovina C, D'Aurelio M, et al. Role of mitochondria in oxidative stress and aging. Ann NY Acad Sci 2002; 959:199-213.
5. Indo HP, Davidson M, Yen HC, et al. Evidence of ROS generation by mitochondria in cells with impaired electron transport chain and mitochondrial DNA damage. Mitochondrion 2007;7:106-118.
6. Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 1997;38: 1155-1160.
7. Yoshii Y, Yoneda M, Ikawa M, et al. Radiolabeled Cu-ATSM as a novel indicator of overreduced intracellular state due to mitochondrial dysfunction: studies with mitochondrial DNA-less r0 cells and cybrids carrying MELAS mitochondrial DNA mutation. Nucl Med Biol 2012;39: 177-185.
8. Donnelly PS, Liddell JR, Lim S, et al. An impaired mitochondrial electron transport chain increases retention of the hypoxia imaging agent diacetylbis (4-methylthiosemicarbazonato) copper II. Proc Natl Acad Sci USA 2012;109:47-52.
9. Ikawa M, Okazawa H, Arakawa K, et al. PET imaging of redox and energy states in stroke-like episodes of MELAS. Mitochondrion 2009;9:144-148.
10. Ikawa M, Okazawa H, Kudo T, Kuriyama M, Fujibayashi Y, Yoneda M. Evaluation of striatal oxidative stress in patients with Parkinson's disease using [62Cu] ATSM PET. Nucl Med Biol 2011;38:945-951.
11. Lohith TG, Kudo T, Demura Y, et al. Pathophysiologic correlation between 62Cu-ATSM and 18F-FDG in lung cancer. J Nucl Med 2009;50:1948-1953.
12. Isozaki M, Kiyono Y, Arai Y, et al. Feasibility of 62Cu-ATSM PET for evaluation of brain ischaemia and misery perfusion in patients with cerebrovascular disease. Eur J Nucl Med Mol Imaging 2011;38:1075-1082.
13. Penfield W, Boldrey E. Somatic motor and sensory representation in the cerebral cortex of man as studied by electrical stimulation. Brain 1937;60:389-443.
14. Kushchayev SV, Moskalenko VF, Wiener PC, et al. The discovery of the pyramidal neurons: Vladimir Betz and a new era of neuroscience. Brain 2012;135:285-300.
15. Rizzolatti G, Luppino G. The cortical motor system. Neuron 2001;31:889-901.
16. Cosottini M, Pesaresi I, Piazza S, et al. Magnetization transfer imaging demonstrates a distributed pattern of microstructural changes of the cerebral cortex in amyotrophic lateral sclerosis. Am J Neuroradiol 2011;32: 704-708.
17. Fitzmaurice PS, Shaw IC, Kleiner HE, et al. Evidence for DNA damage in amyotrophic lateral sclerosis. Muscle Nerve 1996;19:797-798.
18. Shaw PJ, Ince PG, Falkous G, Mantle D. Oxidative damage to protein in sporadic motor neuron disease spinal cord. Ann Neurol 1995;38:691-695.
19. Ferrante RJ, Browne SE, Shinobu LA, et al. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J Neurochem 1997;69: 2064-2074.
20. Shibata N, Nagai R, Uchida K, et al. Morphological evidence for lipid peroxidation and protein glycoxidation in spinal cords from sporadic amyotrophic lateral sclerosis patients. Brain Res 2001;917:97-104.
21. Bogdanov M, Brown RH, Matson W, et al. Increased oxidative damage to DNA in ALS patients. Free Radic Biol Med 2000;29:652-658.
22. Mitsumoto H, Santella RM, Liu X, et al. Oxidative stress biomarkers in sporadic ALS. Amyotroph Lateral Scler 2008;9:177-183.
23. Simpson EP, Henry YK, Henkel JS, Smith RG, Appel SH. Increased lipid peroxidation in sera of ALS patients: a potential biomarker of disease burden. Neurology 2004; 62:1758-1765.
24. Muyderman H, Chen T. Mitochondrial dysfunction in amyotrophic lateral sclerosis: a valid pharmacological target Br J Pharmacol 2014;171:2191-2205.
25. Dexter DT, Carter CJ, Wells FR, et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 1989;52:381-389.
26. Katayama Y, Maeda K, Iizuka T, et al. Accumulation of oxidative stress around the stroke-like lesions of MELAS patients. Mitochondrion 2009;9:306-313.
27. Basken NE, Green MA. Cu(II) bis(thiosemicarbazone) radiopharmaceutical binding to serum albumin: further definition of species dependence and associated substituent effects. Nucl Med Biol 2009;36:495-504.
28. Hueting R, Kersemans V, Cornelissen B, et al. A comparison of the behavior of 64Cu-acetate and 64Cu-ATSM in vitro and in vivo. J Nucl Med 2014;55:128-134.
29. Soon CP, Donnelly PS, Turner BJ, et al. Diacetylbis (N(4)-methylthiosemicarbazonato) copper(II) (CuII(atsm)) protects against peroxynitrite-induced nitrosative damage and prolongs survival in amyotrophic lateral sclerosis mouse model. J Biol Chem 2011;286:44035-44044.
30. McAllum EJ, Lim NK, Hickey JL, et al. Therapeutic effects of Cu(II)(atsm) in the SOD1-G37R mouse model of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2013;14:586-590.
31. Roberts BR, Lim NK, McAllum EJ, et al. Oral treatment with Cu(II)(atsm) increases mutant SOD1 in vivo but protects motor neurons and improves the phenotype of a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci 2014;34:8021-8031.
32. Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. Lancet 2011;377:942-955.
33. Mhatre M, Floyd RA, Hensley K. Oxidative stress and neuroinflammation in Alzheimer's disease and amyotrophic lateral sclerosis: common links and potential therapeutic targets. J Alzheimers Dis 2004;6:147-157.
34. Corcia P, Tauber C, Vercoullie J, et al. Molecular imaging of microglial activation in amyotrophic lateral sclerosis. PLoS One 2012;7:e52941.
35. Ikawa M, Yoneda M, Tanaka M. Energy states in mitochondrial cardiomyopathy: in vivo functional imaging and L-arginine therapy. Circ J 2010;74:2560-2561.
36. Pagani M, Chiò A, Valentini MC, et al. Functional pattern of brain FDG-PET in amyotrophic lateral sclerosis. Neurology 2014;83:1067-1074.
37. Van Laere K, Vanhee A, Verschueren J, et al. Value of 18fluorodeoxyglucose-positron-emission tomography in amyotrophic lateral sclerosis: a prospective study. JAMA Neurol 2014;71:553-561.